Thursday, February 5, 2026
StockstToday.com Logo
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
StocksToday.com Logo
No Result
View All Result
Home Breaking News

Analyst Maintains Positive Outlook on Endava with Adjusted Price Target

Elaine Mendonca by Elaine Mendonca
March 1, 2024
in Breaking News
0
Biotechnology Stock Bull Market
0
SHARES
2
VIEWS
Share on FacebookShare on Twitter

TD Cowen analyst Bryan Bergin has reiterated his positive outlook on Endava (NYSE: DAVA), maintaining an Outperform rating. However, he has adjusted the price target to $52, down from $85. Despite this revision, the average one-year price target for Endava plc – ADR stands at $72.80, with projections ranging from $53.53 to $98.48.

Analysts surveyed by Capital IQ also give Endava an average outperform rating, with a price target range of $53 to $98.48. The company offers technology services and solutions across various industries including payments, financial services, technology, media, telecom, consumer products, retail, mobility, and healthcare.

Endava leverages its Distributed Enterprise Agile scaling framework to help clients develop digital solutions and maximize their business opportunities.

DAVA Stock Plummets 41.76% on March 1, 2024: Pre-Market Gains Offer Hope for Recovery

On March 1, 2024, DAVA stock experienced a significant drop in price, with shares decreasing by $26.65 since the market last closed. This represents a 41.76% drop in value, with the stock closing at $37.17. However, there seems to be some positive movement in pre-market trading, as the stock has risen by $0.72.

Investors and analysts will be closely monitoring DAVA’s performance in the coming days to see if the pre-market gains will hold and if the stock can start to recover from its recent losses. It will be important to watch for any news or developments that could impact the stock’s price movement.

DAVA Stock Analysis: Mixed Performances on March 1, 2024

On March 1, 2024, DAVA stock experienced mixed performances based on the financial data provided by CNN Money. The total revenue for the company stood at $955.89 million for the past year, showing a 9.84% increase compared to the previous year. However, the total revenue for the second quarter was $227.72 million, reflecting a 4.5% decrease compared to the previous quarter.

Similarly, the net income for DAVA was reported at $113.26 million for the past year, holding flat compared to the previous year. However, the net income for the second quarter was $10.36 million, indicating a significant 33.83% decrease compared to the previous quarter.

Furthermore, the earnings per share (EPS) for DAVA stock was $1.95 for the past year, remaining flat compared to the previous year. However, the EPS for the second quarter was $0.18, showing a substantial 34.3% decrease compared to the previous quarter.

Overall, the financial performance of DAVA stock on March 1, 2024, was a mix of positive and negative indicators. Investors and analysts will closely monitor these financial indicators to assess the overall health and performance of DAVA stock in the coming months. It is essential for investors to conduct thorough research and analysis before making any investment decisions based on the financial data provided.

Tags: DAVA
Elaine Mendonca

Elaine Mendonca

Related Posts

NFT projects
Breaking News

The Impact of TikToks Fate on USChina Relations and American Tech Giants

March 16, 2024
Businesses finance
Breaking News

Blackstone Strategic Credit 2027 Term Fund BGB Announces Monthly Dividend of 93 Cents per Share

March 15, 2024
Healthcare-sector
Breaking News

Analyzing Short Interest in Molina Healthcare Inc MOH

March 15, 2024
Next Post
Ai Sleeping

Sleep Quality's Impact on Physical and Financial Well-Being

DVY stock news

Truist Securities Analyst Reiterates Hold Recommendation on Best Buy Co

Finances (2)

Truist Securities Analyst Maintains Hold Rating on Integra Lifesciences with Revised Price Target

Recommended

SKYX Platforms Stock

Marriott Partnership Signals Major Breakthrough for SKYX Platforms

5 months ago
Microsoft Stock

Microsoft’s AI Ambition: A High-Stakes Bet on Future Growth

18 hours ago
Turtle Beach Stock

Turtle Beach Forges PlayStation Alliance with New Gaming Headset

5 months ago
FLO stock news

Cemtrex Shares Surge After Halting Trading Due to Circuit Breaker

2 years ago

Categories

  • AI & Quantum Computing
  • Analysis
  • Analyst Ratings
  • Asian Markets
  • Automotive & E-Mobility
  • Banking & Insurance
  • Bitcoin
  • Blockchain
  • Bonds
  • Breaking News
  • Business & Industry Trends
  • Cannabis
  • Chemicals
  • Commodities
  • Consumer & Luxury
  • Crypto Stocks
  • Cryptocurrency
  • Cyber Security
  • DAX
  • Defense & Aerospace
  • Dividends
  • Dow Jones
  • E-Commerce
  • Earnings
  • Emerging Markets
  • Energy & Oil
  • ETF
  • Ethereum & Altcoins
  • European Markets
  • Forex
  • Gaming & Metaverse
  • Gold & Precious Metals
  • Healthcare
  • Hydrogen
  • Index
  • Industrial
  • Insider Trading
  • IPOs
  • Market Commentary
  • Market News
  • MDAX & SDAX
  • Mergers & Acquisitions
  • Nasdaq
  • Penny Stocks
  • Pharma & Biotech
  • Real Estate & REITs
  • Renewable Energy
  • S&P 500
  • Semiconductors
  • Space
  • Stock Picks
  • Stock Targets
  • Stocks
  • TecDAX
  • Tech & Software
  • Telecommunications
  • Trading & Momentum
  • Turnaround
  • Uncategorized
  • Value & Growth

Topics

Adobe Alibaba Alphabet Amazon AMD Apple ASML BioNTech Bitcoin Broadcom Coca-Cola Coinbase D-Wave Quantum Eli Lilly Fiserv IBM Intel Kraft Heinz Marvell Technology META Micron Microsoft MP Materials MSCI World ETF Newmont Mining NIO Novo Nordisk Nvidia Ocugen Opendoor Oracle Palantir PayPal Plug Power QuantumScape Robinhood Rocket Lab USA Strategy Super Micro Computer Synopsys Tesla Tilray Unitedhealth Uranium Energy Viking Therapeutics
No Result
View All Result

Highlights

CureVac Delisted Following BioNTech Acquisition Completion

Strategic Robotics Partnership Signals New Growth Phase for EOS Defence

NexPoint Residential Trust Sets Date for Annual and Q4 2025 Results

PC Connection Set to Report Full-Year and Fourth Quarter Earnings

Fossil Group Stock Surges Past Key Technical Threshold

NextGen Healthcare: Strategic Wins and Industry Accolades Signal Sustained Momentum

Trending

Rolls Royce Stock
Defense & Aerospace

Rolls-Royce Shares: A Pivotal Period for Growth and Diversification

by Dieter Jaworski
February 5, 2026
0

The coming weeks represent a critical juncture for Rolls-Royce. The company is poised to demonstrate whether it...

Viking Therapeutics Stock

Viking Therapeutics: Investors Await Key Clinical Updates in Forthcoming Report

February 5, 2026
Solana Stock

Solana Faces Billions in Potential Token Supply Releases

February 5, 2026
CureVac Stock

CureVac Delisted Following BioNTech Acquisition Completion

February 5, 2026
EOS Stock

Strategic Robotics Partnership Signals New Growth Phase for EOS Defence

February 5, 2026

StocksToday.com is your one-stop destination for the latest stock news and analysis. We provide in-depth coverage of the stock market, including market news, company news, sector news, IPO news, investment strategies, personal finance, international markets, and more.

Follow us on social media:

Recent News

  • Rolls-Royce Shares: A Pivotal Period for Growth and Diversification
  • Viking Therapeutics: Investors Await Key Clinical Updates in Forthcoming Report
  • Solana Faces Billions in Potential Token Supply Releases

Category

  • About
  • Advertise
  • Careers
  • Contact
  • Imprint
  • Privacy Policy
  • Terms of Service

© 2023 StocksToday.com

No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing

© 2023 StocksToday.com